openPR Logo
Press release

In safe hands with the GLP checklist

07-30-2018 04:45 PM CET | Science & Education

Press release from: BINDER GmbH

The "Good Laboratory Practice" regulatory mandate (GLP for short) was introduced in 1978 after the FDA (U.S. Food and Drug Administration) had already identified significant deficiencies in toxicological studies in the years preceding. The German Chemicals Act was introduced in an effort to ensure that newly approved drugs for human consumption really are safe and minimize any and all risks.
The values of transparency, traceability, assignment of responsibilities, and safekeeping are particularly important in this context. The GLP also checks personal, organizational, and spatial requirements before approving a new drug.
To achieve GLP compliance, specific requirements must be met by the laboratory units (e.g., climate chambers) used in the development of the drugs concerned. Maintenance documents and repair documents must be available to consult when a new drug is being tested. To ensure adherence to all rules and regulations on the unit side during the approval process, BINDER has developed a very helpful checklist for its customers. The checklist guides users through the most important points that are relevant to the compliance of their workflows. Questions include, for example: Is a continuous CO2 supply ensured? Are there back-up chambers available for emergencies? Has a cleaning plan or a maintenance plan been drawn up? All of these questions will help users who are working with a simulation chamber and wish to ensure compliance with the quality guidelines of the GLP regulation.

BINDER temperature, climate, and environmental simulation chambers are the centerpieces of modern laboratories. Designed to meet the highest demands in scientific and industrial fields, they enable the accurate simulation of biological, chemical, and physical environmental conditions. With cutting-edge technology and pioneering innovations, BINDER develops products that provide real added value for the customer. We apply our expertise and feel for the requirements of dynamic, day-to-day work in research facilities to support the widest range of projects and processes in an optimum way. After all, our aim is nothing less than making a contribution to the health, quality of life, and safety of people.

Anne Lenze
PR und Event Specialist

BINDER Central Services GmbH & Co. KG
Im Mittleren Ösch 5
D-78532 Tuttlingen

Phone: +49 7462 / 2005 - 632
Fax: +49 7462 / 2005 - 93 632


This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release In safe hands with the GLP checklist here

News-ID: 1153087 • Views:

More Releases from BINDER GmbH

A new innovation from BINDER: The fail-safe function
A new innovation from BINDER: The fail-safe function
BINDER incubators are the best on the market. Why is this? There is a simple answer in the first instance: Because they are constructed in as straightforward a way as possible, they are incredibly reliable. The risk of the cultures inside a BINDER incubator becoming contaminated is reduced to a minimum. But BINDER customers have high standards and want to know more about the details. This is exactly where the

More Releases for GLP

GLP Analogs Market Report, History and Forecast 2020-2026|Novo Nordisk, AstraZen …
" Los Angeles, United States – – QY Research offers an overarching research and analysis-based study on the global GLP Analogs market, covering growth prospects, market development potential, profitability, supply and demand, and other important subjects. The report presented here comes out as a highly reliable source of information and data on the global GLP Analogs market. The researchers and analysts who have prepared the report used an advanced research methodology
Glucagon Like Peptide-1 (GLP-1) Agonists Market - key players covered:GSK, Sanof …
Los Angeles, United State, –The report titled Global Glucagon Like Peptide-1 (GLP-1) Agonists Market is one of the most comprehensive and important additions to QY Research’s archive of market research studies. It offers detailed research and analysis of key aspects of the global Glucagon Like Peptide-1 (GLP-1) Agonists market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer
Glucagon-Like Peptide-1 (Glp-1) Analogs Market | Global Opportunity Analysis, 20 …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
The Global Report Focuses on Glucagon Like Peptide-1 (GLP-1) Agonists Market 201 …
"The Report Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2016 Research Report provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. -" The Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2016 Research Report is a professional and in-depth study on the current state of the Glucagon like peptide-1 (GLP-1) agonists industry. The report provides a basic overview of the industry including definitions, classifications, applications and
Sysmex Europe and GLP Systems to attend Euromedlab
Norderstedt, Germany, 21 May 2013 – Healthcare solution specialist Sysmex Europe and lab automation experts GLP Systems recently announced their long-term cooperation in the field of laboratory automation. Now both companies are attending Euromedlab in Milan from 19-23 May – and are looking forward to answering any queries. With a brand new transport concept, modular solutions and real freedom from manufacturers, they are confident they are introducing a game changer
Pharmacelsus' GLP implementation exemplary for European CROs
Scientists of the European Center for Validation of Alternative Methods (ECVAM) attended a GLP workshop at Pharmacelsus GmbH Saarbrücken, 4. Juni 2009 - Pharmacelsus, a CRO specialized in preclinical test services, obtained GLP-certification covering the complete portfolio in November 2008. The company is not only able to perform accompanying analytical services for clinical studies in addition to its preclinical services, but also decided to share its knowledge on the GLP